Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pin Yi

Showing results (161-170 of 174) with videos related to

Pageof 18
Sort By:
Molecular Oncology|January 4, 2020
A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancerYao Huang, Sai-Qun Lv, Pin-Yi Liu, et al.
The Journal of Clinical Investigation|November 3, 2015
Histone deacetylase 6 inhibition enhances oncolytic viral replication in gliomaHiroshi Nakashima, Johanna K Kaufmann, Pin-Yi Wang, et al.
Oncotarget|February 2, 2017
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationMark A Currier, Les Sprague, Tilat A Rizvi, et al.
International Journal of Molecular Sciences|August 12, 2023
The Role of Macrophages in Connective Tissue Disease-Associated Interstitial Lung Disease: Focusing on Molecular Mechanisms and Potential Treatment StrategiesChia-Chun Tseng, Ya-Wen Sung, Kuan-Yu Chen, et al.
Iscience|July 19, 2021
Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcomaMary Frances Wedekind, Katherine E Miller, Chun-Yu Chen, et al.
Molecular Therapy. Methods & Clinical Development|August 13, 2025
Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engagerMark A Currier, Allen Reha, Brian Hutzen, et al.
Frontiers in Immunology|July 24, 2024
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
Frontiers in Immunology|July 24, 2024
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
Molecular Therapy. Oncology|November 4, 2024
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcomaEmily M Ringwalt, Mark A Currier, Andrea M Glaspell, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone SarcomaEmily M Ringwalt, Mark A Currier, Andrea M Glaspell, et al.
Pageof 18

Showing results (161-170 of 174) with videos related to

Sort By:
Pageof 18
Molecular Oncology|January 4, 2020
A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancerYao Huang, Sai-Qun Lv, Pin-Yi Liu, et al.
The Journal of Clinical Investigation|November 3, 2015
Histone deacetylase 6 inhibition enhances oncolytic viral replication in gliomaHiroshi Nakashima, Johanna K Kaufmann, Pin-Yi Wang, et al.
Oncotarget|February 2, 2017
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationMark A Currier, Les Sprague, Tilat A Rizvi, et al.
International Journal of Molecular Sciences|August 12, 2023
The Role of Macrophages in Connective Tissue Disease-Associated Interstitial Lung Disease: Focusing on Molecular Mechanisms and Potential Treatment StrategiesChia-Chun Tseng, Ya-Wen Sung, Kuan-Yu Chen, et al.
Iscience|July 19, 2021
Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcomaMary Frances Wedekind, Katherine E Miller, Chun-Yu Chen, et al.
Molecular Therapy. Methods & Clinical Development|August 13, 2025
Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engagerMark A Currier, Allen Reha, Brian Hutzen, et al.
Frontiers in Immunology|July 24, 2024
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
Frontiers in Immunology|July 24, 2024
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
Molecular Therapy. Oncology|November 4, 2024
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcomaEmily M Ringwalt, Mark A Currier, Andrea M Glaspell, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone SarcomaEmily M Ringwalt, Mark A Currier, Andrea M Glaspell, et al.
Pageof 18